Sunshine Biopharma, Inc. (SBFM) Analyst Estimates Annual - Discounting Cash Flows
SBFM
Sunshine Biopharma, Inc.
SBFM (NASDAQ)
Period Ending: 2026
12-31
2025
12-31
2024
12-31
2023
12-31
Number of Analysts 1 1 1 1
Estimated Revenue
Low 50 37.73 37.8 21.03
Average 50 37.73 37.8 21.03
High 50 37.73 37.8 21.03
Estimated EBITDA
Low -33.07 -24.95 -25 -13.91
Average -33.07 -24.95 -25 -13.91
High -33.07 -24.95 -25 -13.91
Estimated EBIT
Low -33.19 -25.05 -25.09 -13.96
Average -33.19 -25.05 -25.09 -13.96
High -33.19 -25.05 -25.09 -13.96
Estimated Net Income
Low -0.225 -0.709 -2.89 -224.6
Average -0.225 -0.709 -2.89 -224.6
High -0.225 -0.709 -2.89 -224.6
Estimated SGA Expenses
Low 188.9 142.6 142.8 79.48
Average 188.9 142.6 142.8 79.48
High 188.9 142.6 142.8 79.48
Estimated EPS
Low -0.32 -1.01 -4.12 -320
Average -0.32 -1.01 -4.12 -320
High -0.32 -1.01 -4.12 -320
discounting cash flows home logo

Discounting Cash Flows

Are you finding our services helpful? Review us on trustpilot logo Trustpilot
Have a question? Contact us
Want to become our sponsor?
Check out our Affiliate Program